Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for 89BIO (ETNB : NSDQ)
 
 • Company Description   
89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.

Number of Employees: 93

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.16 Daily Weekly Monthly
20 Day Moving Average: 2,048,865 shares
Shares Outstanding: 145.98 (millions)
Market Capitalization: $1,483.20 (millions)
Beta: 1.28
52 Week High: $11.84
52 Week Low: $4.16
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.88% -5.28%
12 Week 83.72% 56.92%
Year To Date 29.92% 21.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
655 MONTGOMERY STREET SUITE 1500
-
SAN FRANCISCO,CA 94111
USA
ph: 415-432-9270
fax: -
investors@89bio.com http://www.89bio.com
 
 • General Corporate Information   
Officers
Rohan Palekar - Chief Executive Officer and Director
Ryan Martins - Chief Financial Officer
Steven Altschuler - Director
Edward Morrow Atkinson - Director
Martin Babler - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 282559103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 145.98
Most Recent Split Date: (:1)
Beta: 1.28
Market Capitalization: $1,483.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 13.52% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.45
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 9.26%
vs. Previous Quarter: 51.96%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -81.44
12/31/24 - -81.38
ROA
06/30/25 - -
03/31/25 - -70.17
12/31/24 - -70.04
Current Ratio
06/30/25 - -
03/31/25 - 18.03
12/31/24 - 13.19
Quick Ratio
06/30/25 - -
03/31/25 - 18.03
12/31/24 - 13.19
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 4.15
12/31/24 - 3.34
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.06
12/31/24 - 0.09
Debt-to-Capital
06/30/25 - -
03/31/25 - 5.60
12/31/24 - 8.19
 

Powered by Zacks Investment Research ©